Ocugen, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on the stock and has a $7.00 price target.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Swayampakula Ramakanth’s rating is based on the promising progress of Ocugen’s gene therapy programs and the company’s financial stability. The pivotal study for Stargardt disease is enrolling faster than anticipated, and the company has sufficient funds to support operations through the second quarter of 2026.
Additionally, Ocugen’s ocular gene therapies have demonstrated compelling efficacy and a favorable safety profile, which, despite challenges in the gene therapy sector, positions the company well in the market. The recent licensing agreement with Kwangdong Pharmaceutical for OCU400 in South Korea further underscores industry interest and potential revenue growth. These factors collectively contribute to the Buy rating, suggesting that Ocugen’s stock is undervalued and presents a good opportunity for long-term investors.